Skip to main
BWAY

Brainsway (BWAY) Stock Forecast & Price Target

Brainsway (BWAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrainsWay Ltd's proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology has received positive regulatory recognition, exemplified by the FDA approval of the ProlivRx at-home neuromodulation device, marking a significant milestone in expanding the treatment landscape for mental health disorders. The company is experiencing an expansion in forward earnings multiples, with the financial evaluation reflecting an intrinsic value of $100 million associated with its strategic investment in Neurolief, indicating robust growth potential. Additionally, the ongoing clinical trials and increasing acceptance of pay-per-use models signal a favorable market trend and potential for increased adoption of Deep TMS therapies among a broader range of medical specialists.

Bears say

The financial outlook for BrainsWay Ltd appears negative due to several significant risks that could impact its growth trajectory. These risks include the slower-than-anticipated adoption of its Deep TMS systems, challenges in securing reimbursement and expanding market access, and hurdles in advancing its technology into new indications. Furthermore, there is a potential for long-term dilution risk, which may adversely affect shareholder value and overall financial stability.

Brainsway (BWAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Brainsway (BWAY) Forecast

Analysts have given Brainsway (BWAY) a Buy based on their latest research and market trends.

According to 2 analysts, Brainsway (BWAY) has a Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Brainsway (BWAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.